NMPA accepts marketing registration application for Velsipity domestic manufacturing transfer
September 17, 2026
Source: drugdu
31
On September 17, Everest Medicines announced that CDE of the NMPA has accepted the marketing registration application for Velsipity (etrasimod arginine tablets) for the transfer of manufacturing from overseas to domestic production, and has granted Priority Review. Local production is expected to commence in 2027. Velsipity was approved by NMPA in February 2026 for adult patients with moderate to severe active ulcerative colitis (UC) who have an inadequate response, loss of response, or intolerance to conventional therapies or biologics.
Source: https://finance.eastmoney.com/a/202609173876680142.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- Novartis acquires Sironax’s blood-brain barrier delivery platform for $125 million September 17, 2026
- IASO Bio’s in vivo CAR-T IASO208 receives FDA clinical trial clearance September 17, 2026
- Ziprasidone mesylate from SSY Group has been approved for registration as an active pharmaceutical ingredient. September 17, 2026
- Kanghong Pharmaceutical’s research on Shugan Jieyu Capsules won the first prize of the Science and Technology Award of the Chinese Pharmaceutical Association. September 17, 2026
- Johnson & Johnson celebrates the launch of Rybrevant FASPRO (amivantamab subcutaneous injection) in China September 17, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
